Balchem Corporation

NasdaqGS:BCPC Aktierapport

Börsvärde: US$5.2b

Balchem Framtida tillväxt

Future kriterier kontrolleras 1/6

Balchem förväntas öka vinsten och intäkterna med 6.8% och 5.6% per år respektive medan EPS förväntas växa med 6.4% per år.

Viktig information

6.8%

Tillväxttakt i vinsten

6.40%

Tillväxttakt för EPS

Chemicals vinsttillväxt17.1%
Intäkternas tillväxttakt5.6%
Framtida avkastning på eget kapitaln/a
Bevakning av analytiker

Low

Senast uppdaterad08 May 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Seeking Alpha • Mar 27

Balchem: An Attractive Valuation Makes This Stock A Buy

Summary Balchem delivered strong Q4 results, with revenue up nearly 10% year-over-year and all segments posting growth. BCPC boasts a 17-year streak of double-digit dividend hikes, supported by a payout ratio consistently below 20%. The stock trades at a roughly 25% discount to its estimated fair value, with robust forward return potential exceeding 14%. I rate BCPC a 'Buy', citing resilient segment demand, disciplined capital allocation, and attractive free cash flow valuation despite raw material and tariff risks. Read the full article on Seeking Alpha
Ny analys • Mar 13

Long-Term Nutrition And Health Trends Will Support Stronger Margins And Earnings Potential

Catalysts About Balchem Balchem supplies specialty nutrients and ingredients for human, animal and plant health, along with performance gases and related solutions. What are the underlying business or industry changes driving this perspective?
Ny analys • Feb 26

Encapsulation Investments And International Expansion Will Shape Balanced Future For Nutrition Specialist

Catalysts About Balchem Balchem produces specialty nutrition and ingredient solutions for human, animal and plant health, along with performance gases. What are the underlying business or industry changes driving this perspective?
Analysuppdatering • Feb 17

BCPC: Dividend Increase And Buyback Program Will Support Steady Future Returns

Analysts kept their Balchem fair value estimate broadly steady at $191, pointing to only very small tweaks in assumptions such as discount rate, long term revenue growth, profit margin and future P/E as the basis for maintaining their target level. What's in the News On December 9, 2025, Balchem Corporation's Board of Directors declared an annual dividend of $0.96 per share, payable on January 20, 2026, to stockholders of record as of December 23, 2025.
Analysartikel • Feb 15

If EPS Growth Is Important To You, Balchem (NASDAQ:BCPC) Presents An Opportunity

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysuppdatering • Feb 03

BCPC: Share Repurchases And Higher Dividend Will Support Attractive Future Returns

Analysts have maintained their fair value estimate for Balchem at US$191. They have made only minimal adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, indicating that their overall view on the stock's valuation drivers remains essentially unchanged.
Analysartikel • Feb 01

Is Now An Opportune Moment To Examine Balchem Corporation (NASDAQ:BCPC)?

Balchem Corporation ( NASDAQ:BCPC ), is not the largest company out there, but it saw a decent share price growth of...
Analysuppdatering • Jan 20

BCPC: Share Repurchases And Rising Dividend Will Support Attractive Future Returns

Analysts have maintained their Balchem fair value estimate at US$191, with only small tweaks to the discount rate, revenue growth, profit margin, and forward P/E assumptions. This reflects a largely unchanged view on the stock's risk and earnings profile.
Analysuppdatering • Jan 05

BCPC: Share Repurchases And Dividend Increases Will Support Attractive Future Returns

Analysts kept their fair value estimate for Balchem steady at US$191, pointing to only very small model tweaks in the discount rate, revenue growth, margin and forward P/E assumptions rather than any change in their overall view of the company. What's in the News Balchem Corporation announced a share repurchase program authorizing the company to buy back up to 4,000,000 shares, with no expiration date on the program (Key Developments).
Analysuppdatering • Dec 20

BCPC: Share Repurchases And Dividend Increases Will Drive Attractive Future Returns

Analysts have maintained their price target on Balchem at approximately $191.00. This reflects only marginal tweaks to underlying assumptions such as discount rate, revenue growth, and profit margin, rather than a material change in their outlook.
Analysuppdatering • Dec 06

BCPC: Share Repurchases Will Support Attractive Long Term Return Potential

Analysts have lowered their price target on Balchem by approximately $9 to about $191 per share, reflecting more cautious assumptions around revenue growth and profit margins, even though long term valuation multiples are slightly higher. What's in the News Completed a long running share repurchase program, buying back a total of 3,475,622 shares, or about 12.76% of shares outstanding, for approximately $190.58 million since the authorization began in 1999 (Key Developments) During the most recent quarter from July 1, 2025 to September 30, 2025, repurchased 95,760 shares, roughly 0.3% of shares outstanding, for $15.42 million as the final tranche under the existing buyback plan (Key Developments) Valuation Changes The Fair Value Estimate has fallen modestly from about $200.33 to $191.00 per share, reflecting a slightly more conservative outlook.
Analysartikel • Dec 01

Balchem (NASDAQ:BCPC) Is Experiencing Growth In Returns On Capital

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
Analysartikel • Oct 10

Some Shareholders Feeling Restless Over Balchem Corporation's (NASDAQ:BCPC) P/E Ratio

Balchem Corporation's ( NASDAQ:BCPC ) price-to-earnings (or "P/E") ratio of 31.9x might make it look like a strong sell...
Analysartikel • Sep 26

Balchem (NASDAQ:BCPC) Could Easily Take On More Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysartikel • Aug 26

Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Balchem fair value estimate is US$174 With US$162 share price...
Analysartikel • Jul 21

Balchem (NASDAQ:BCPC) Is Looking To Continue Growing Its Returns On Capital

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysartikel • Jun 23

These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Safely

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysartikel • May 26

When Should You Buy Balchem Corporation (NASDAQ:BCPC)?

Balchem Corporation ( NASDAQ:BCPC ), might not be a large cap stock, but it saw a decent share price growth of 10% on...
Analysartikel • May 12

Estimating The Intrinsic Value Of Balchem Corporation (NASDAQ:BCPC)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Balchem fair value estimate is US$157 With US$165 share price...
Seeking Alpha • Oct 28

Balchem's Q3 Shows Record Earnings And Valuation Pressure

Summary Balchem Corporation shows strong long-term growth potential in high-margin segments and product innovation, but faces challenges in Animal Nutrition & Health and rising costs. Balchem's financial momentum in Q3 2024 includes record earnings, improved margins, and significant debt reduction, despite missing revenue estimates. BCPC stock's high P/E ratio of 39.82x suggests big market expectations, but the current valuation may be too high given existing challenges. I rate Balchem as a “Hold” due to high valuation, operational challenges, and potential seasonal slowdown, advising cautious investors to wait for a better entry point. Read the full article on Seeking Alpha
User avatar
Ny analys • Aug 29

Innovating In Nutrition And Health Sectors Drives Strong Financial Growth And Market Expansion

Launch of Optifolin+ in the nutrition segment and strong Human Nutrition & Health sales indicate potential for market share expansion and sustained revenue growth.
Seeking Alpha • May 10

Balchem: A Tale Of Two Businesses

Summary Balchem Corporation's Q1 2024 earnings surpassed expectations, but the company's full-year bottom-line expansion could be slower than what it achieved for the first quarter. The Human Nutrition & Health segment is riding on the supplements market's growth, while the Animal Nutrition & Health segment is encountering stiff competition in the European animal feed market. It is a tale of two businesses for BCPC, which implies that the stock warrants a Neutral or Hold rating. Read the full article on Seeking Alpha
Seeking Alpha • Feb 21

Balchem: Potential Turnaround Is In The Price

Summary Balchem registered a -2.5% top-line miss for the fourth quarter of 2023, which is attributable to the underperformance of its Animal Nutrition business. BCPC is well-positioned to achieve positive top line and earnings expansion in the current year, but I deem the stock's valuations to be fair. The Company continues to be rated as a Hold, as my opinion is that the expected 2024 turnaround for BCPC is priced in. Read the full article on Seeking Alpha

Prognoser för vinst- och omsättningstillväxt

NasdaqGS:BCPC - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/20281,241N/AN/AN/A1
12/31/20271,1651792122454
12/31/20261,1061701892284
3/31/20261,057158176220N/A
12/31/20251,037155173217N/A
9/30/20251,014149162202N/A
6/30/2025986143153187N/A
3/31/2025965137151185N/A
12/31/2024954128146182N/A
9/30/2024942122162197N/A
6/30/2024932117159192N/A
3/31/2024930115147182N/A
12/31/2023922109146184N/A
9/30/2023926103118158N/A
6/30/202394199106153N/A
3/31/202394699117166N/A
12/31/202294210589139N/A
9/30/202292310991141N/A
6/30/202287710995139N/A
3/31/202284210286127N/A
12/31/202179996123161N/A
9/30/202176793128164N/A
6/30/202174490125160N/A
3/31/202171588134169N/A
12/31/202070485117150N/A
9/30/202068983108136N/A
6/30/202067382116143N/A
3/31/20206618199125N/A
12/31/201964480N/A124N/A
9/30/201964180N/A131N/A
6/30/201963778N/A121N/A
3/31/201963978N/A116N/A
12/31/201864479N/A119N/A
9/30/2018639100N/A110N/A
6/30/201863597N/A112N/A
3/31/201861894N/A113N/A
12/31/201759590N/A111N/A
9/30/201757664N/A107N/A
6/30/201756462N/A97N/A
3/31/201755660N/A101N/A
12/31/201655356N/A108N/A
9/30/201654556N/A105N/A
6/30/201654756N/A110N/A
3/31/201654356N/A107N/A
12/31/201555260N/A104N/A
9/30/201558263N/A115N/A
6/30/201560364N/A108N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: BCPC s prognostiserade vinsttillväxt ( 6.8% per år) är över sparkvoten ( 3.5% ).

Resultat vs marknad: BCPC s intäkter ( 6.8% per år) förväntas växa långsammare än marknaden för US ( 16.7% per år).

Höga tillväxtresultat: BCPC s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: BCPC s intäkter ( 5.6% per år) förväntas växa långsammare än marknaden för US ( 11.6% per år).

Hög tillväxtintäkter: BCPC s intäkter ( 5.6% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om BCPC s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/11 18:34
Aktiekurs vid dagens slut2026/05/08 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Balchem Corporation bevakas av 9 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Robert LabickCJS Securities, Inc.
Timothy RameyD.A. Davidson & Co.
Raghuram SelvarajuH.C. Wainwright & Co.